Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638220 · ClinicalTrials.gov registry record
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
A clinical trial, sponsored by Travere Therapeutics.
- Completed
- Registry status
- 442
- Enrollment target
NCT02638220: Completed study, sponsored by Travere Therapeutics.
NCT02638220 is a clinical trial that has completed, run by Travere Therapeutics. The registered enrollment target is 442 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02638220 has completed, sponsored by Travere Therapeutics.
- COMPLETED
- Registry status
- 442 participants
- Enrollment target
Study Summary
Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.
Primary Outcome
genetic test results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-02-19 |
What the finished NCT02638220 record still lists
NCT02638220 is an observational study that tracks outcomes without assigning an intervention. The registered 442 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02638220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02638220 about?
NCT02638220 is a clinical study titled "Cerebrotendinous Xanthomatosis (CTX) Prevalence Study". Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.
What is the current status of trial NCT02638220?
This trial is currently completed. The enrollment target is 442 participants. The study started on 2015-09. Estimated completion is 2021-02-19.
Who is sponsoring clinical trial NCT02638220?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT06659029 · 442 participants
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia